SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS

Taher, A.; Porter, J.; Viprakasit, V.; Kattamis, A.; Chuncharunee, S.; Sutcharitchan, P.; Siritanaratkul, N.; Galanello, R.; Karakas, Z.; Habr, D.; Zhu, Z.; Cappellini, M.

SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS / A. Taher, J. Porter, V. Viprakasit, A. Kattamis, S. Chuncharunee, P. Sutcharitchan, N. Siritanaratkul, R. Galanello, Z. Karakas, D. Habr, Z. Zhu, M. Cappellini. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 98:s1(2013 Jun), pp. 427-428. ((Intervento presentato al 18. convegno Congress of the European Hematology Association (EHA) tenutosi a Stockholm nel 2013.